Line
|
Candle
1D
5D
1M
3M
6M
YTD
1Y
5Y
High
0.9066
Open
0.840
VWAP
0.88
Vol
163.07K
Mkt Cap
56.35M
Low
0.8335
Amount
144.12K
EV/EBITDA(TTM)
--
Total Shares
54.31M
EV
54.87M
EV/OCF(TTM)
--
P/S(TTM)
1.24
CytoSorbents Corporation is engaged in the treatment of life-threatening conditions in intensive care (ICU) and cardiac surgery using blood purification via its proprietary polymer adsorption technology. The Company’s flagship product, CytoSorb, is an extracorporeal cytokine absorber, designed to reduce the cytokine storm or cytokine release syndrome that could otherwise cause massive inflammation, organ failure and death in common critical illnesses, such as sepsis, burn injury, trauma, lung injury, cytokine release syndrome due to cancer immunotherapy, and pancreatitis. Its other products include CytoSorb, animal-targeted VetResQ, DrugSorb-ATR and ECOS-300CY. Its other product candidates under development, including CytoSorb XL, BetaSorb, ContrastSorb, DrugSorb, HemoDefend-RBC, HemoDefend-BGA, K+ontrol, and others consist of a cartridge containing adsorbent, porous polymer beads, although the polymers used in these devices are physically different.
Show More
Market Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q2
FY2025Q3
FY2025Q4
9.99M
+0.92%
--
--
10.66M
+13.56%
--
--
11.46M
+13.5%
--
--
Estimates Revision
The market is revising Downward the revenue expectations for Cytosorbents Corporation (CTSO) for FY2025, with the revenue forecasts being adjusted by -11.94% over the past three months. During the same period, the stock price has changed by -23.73%.
Revenue Estimates for FY2025
Revise Downward
-11.94%
In Past 3 Month
Stock Price
Go Down
-23.73%
In Past 3 Month
1 Analyst Rating
11.11% Upside
Wall Street analysts forecast CTSO stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for CTSO is 1.00 USD with a low forecast of 1.00 USD and a high forecast of 1.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
0 Buy
1 Hold
0 Sell
Hold
11.11% Upside
Current: 0.900
Low
1.00
Averages
1.00
High
1.00
11.11% Upside
Current: 0.900
Low
1.00
Averages
1.00
High
1.00
HC Wainwright & Co.
Sean Lee
Hold
Reiterates
$1
2025-05-15
New
Reason
HC Wainwright & Co.
Sean Lee
Price Target
$1
2025-05-15
New
Reiterates
Hold
Reason
D. Boral Capital
Jason Kolbert
Strong Buy
Maintains
$10
2025-05-15
New
Reason
D. Boral Capital
Jason Kolbert
Price Target
$10
2025-05-15
New
Maintains
Strong Buy
Reason
D. Boral Capital
Jason Kolbert
Strong Buy
Maintains
$10
2025-05-02
Reason
D. Boral Capital
Jason Kolbert
Price Target
$10
2025-05-02
Maintains
Strong Buy
Reason
HC Wainwright & Co.
Sean Lee
Hold
Reiterates
$1
2025-04-03
Reason
HC Wainwright & Co.
Sean Lee
Price Target
$1
2025-04-03
Reiterates
Hold
Reason
D. Boral Capital
Jason Kolbert
Strong Buy
Maintains
$10
2025-04-01
Reason
D. Boral Capital
Jason Kolbert
Price Target
$10
2025-04-01
Maintains
Strong Buy
Reason
D. Boral Capital
Jason Kolbert
Strong Buy
Maintains
$10
2025-01-13
Reason
D. Boral Capital
Jason Kolbert
Price Target
$10
2025-01-13
Maintains
Strong Buy
Reason
D. Boral Capital says CytoSorbents reported a strong Q4, with product revenue growth estimated between 22% and 25% year-over-year. The company also demonstrated a significant gross margin rebound to around 70%, underscoring operational resilience and efficiency improvements, the analyst tells investors in a research note. D. Boral believes the results highlight CytoSorbents' strong execution and the growing demand for CytoSorb, its flagship product. The firm keeps a Buy rating on the shares with a $10 price target.
See All Ratings
Valuation Metrics
The current forward P/E ratio for Cytosorbents Corp (CTSO.O) is -3.58, compared to its 5-year average forward P/E of -14.12. For a more detailed relative valuation and DCF analysis to assess Cytosorbents Corp 's fair value, click here.
Forward PE
The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
N/A
5Y Average PE
-14.12
Current PE
-3.58
Overvalued PE
2.43
Undervalued PE
-30.68
Forward EV/EBITDA
The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
N/A
5Y Average EV/EBITDA
-193.67
Current EV/EBITDA
-5.92
Overvalued EV/EBITDA
295.51
Undervalued EV/EBITDA
-682.86
Forward PS
The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
Fair
5Y Average PS
4.01
Current PS
1.17
Overvalued PS
6.89
Undervalued PS
1.13
Financials
Annual
Quarterly
FY2025Q1
YoY :
-10.82%
8.73M
Total Revenue
FY2025Q1
YoY :
-20.04%
-3.89M
Operating Profit
FY2025Q1
YoY :
-76.75%
-1.48M
Net Income after Tax
FY2025Q1
YoY :
-100.00%
N/A
EPS - Diluted
FY2025Q1
YoY :
-29.14%
-3.51M
Free Cash Flow
FY2025Q1
YoY :
+5.94%
71.13
Gross Profit Margin - %
FY2025Q1
YoY :
-100.00%
N/A
FCF Margin - %
FY2025Q1
YoY :
-100.00%
N/A
Net Margin - %
Trading Trends
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
3
47.3K
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
0-3
Months
0.0
Volume
0
3-6
Months
0.0
Volume
0
6-9
Months
0.0
Volume
0
0-12
Months
404.9K
Volume
2
Bought
0-3
0
0.0
Volume
Months
3-6
2
168.4K
Volume
Months
6-9
0
0.0
Volume
Months
0-12
0
0.0
Volume
Months
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
3
47.3K
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
CTSO News & Events
Events Timeline
2025-05-14 (ET)
2025-05-14
16:03:17
CytoSorbents reports Q1 EPS (2c) vs. (11c) last year
2025-05-01 (ET)
2025-05-01
16:45:56
CytoSorbents: FDA issues denial letter for De Novo Request for DrugSorb-ATR
2025-03-31 (ET)
2025-03-31
16:18:36
CytoSorbents reports Q4 adjusted EPS (3c) vs. (17c) last year
Sign Up For More Events
Sign Up For More Events
News
9.5
05-14PRnewswirePinnedCytoSorbents Reports First Quarter 2025 Financial Results and Provides Business Update
4.0
05-02BenzingaD. Boral Capital Maintains Buy on CytoSorbents, Maintains $10 Price Target
7.0
05-01PRnewswireCytoSorbents Provides Regulatory Update for DrugSorb-ATR
Sign Up For More News
People Also Watch
NVDA
NVIDIA Corp
135.400
USD
+0.42%
MSFT
Microsoft Corp
454.270
USD
+0.25%
AAPL
Apple Inc
211.260
USD
-0.09%
META
Meta Platforms Inc
640.340
USD
-0.55%
TSLA
Tesla Inc
349.980
USD
+2.09%
XOM
Exxon Mobil Corp
108.190
USD
-0.36%
ORCL
Oracle Corp
160.490
USD
+0.68%
WMT
Walmart Inc
98.240
USD
+1.96%
AVGO
Broadcom Inc
228.610
USD
-1.73%
AMZN
Amazon.com Inc
205.590
USD
+0.20%
FAQ
What is Cytosorbents Corp (CTSO) stock price today?
The current price of CTSO is 0.9 USD — it has increased 7.79 % in the last trading day.
What is Cytosorbents Corp (CTSO)'s business?
What is the price predicton of CTSO Stock?
What is Cytosorbents Corp (CTSO)'s revenue for the last quarter?
What is Cytosorbents Corp (CTSO)'s earnings per share (EPS) for the last quarter?
What changes have occurred in the market's expectations for Cytosorbents Corp (CTSO)'s fundamentals?
How many employees does Cytosorbents Corp (CTSO). have?